Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2018 / N 2

Опыт моделирования болезни Паркинсона: анализ поведенческих нарушений
А.В. Ставровская, Н.Г. Ямщикова, А.С. Ольшанский, А.С. Гущина

References

1. Illarioshkin SN. Conformational brain diseases. Moscow: Yanus-K; 2003. 248 p. (In Russian).
2. Stavrovskaya AV, Konorova IL, Illarioshkin SN, Fedorova TN, Stelmashuck EV, Yamshchikova NG, Stvolinskiy SL, Henrikhs EE, Konovalov EE. Modeling technologies of nervous system diseases. In: Neurology of the XXI century: diagnostic, therapeutic and research technologies: a guide for doctors. 3-vol. set. Piradov MA, Illarioshkin SN, Tanashyan MM, editors. III. Modern research technologies in experimental neurology. Moscow: ATMO; 2015: 73-133 (In Russian).
3. Blesa J, Przedborski S. Parkinson’s disease: animal models and dopaminergic cell vulnerability. Frontiers in Neuroanatomy 2014 Dec;8:155.
4. Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. Journal of Neurochemistry 2007 Oct;103(1):145-56.
5. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego, CA: Academic Press; 1998. 456 p.
6. Alves CS, Andreatini R, da Cunha C, Tufik S, Vital MA. Phosphatidylserine reverses reserpine-induced amnesia. European Journal of Pharmacology 2000 Sep;404(1-2):161-7.
7. Voronkov DN, Khudoerkov RM, Dovedova EL. Changes of neuroglial interactions in nigrostriatal brain structures at simulating of dopamine system dysfunction. SS Korsakov Journal of Neurology and Psychiatry 2013;113(7):47-51 (In Russian).
8. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiology of Disease 2009 Oct;36(1):96-102.
9. Yamshchikova ND, Stavrovskaya AV, Olshanskiy AS, Miroshnichenko EV, Shugalev NP. Features of research behavior of rats in experimental parkinsonism. In: Functional hemispheric asymmetry and brain plasticity. Proceedings of the all-Russian conference with international participation. Illarioshkin SN, Fokin VF, editors. Moscow; 2012: 434-8.
10. Voronkov DN, Dikalova YuV, Khudoerkov RM, Yamshchikova NG. Brain nigrostriatal system changes in rotenone-induced parkinsonism (quantitative immune-morphological study). Annals of Clinical and Experimental Neurology 2013;7(2):34-8 (In Russian).
11. Handley SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacology & Therapeutics 1995 Apr;66(1):103-48.
12. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends in Pharmacological Sciences 2009 Sep;30(9):475-83.
13. Massano J, Bhatia KP. Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management. Cold Spring Harbor Perspectives in Medicine 2012 Jun;2(6):a008870.
14. Betarbet R, Sherer T, Greenamyre T. Animal models of Parkinson’s disease. BioEssays 2002 Apr;24(4):308-18.
15. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998 May;50(5):1346-50.
16. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 1997 Jun;48(6):1583-8.
17. Sachs C, Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochemical Pharmacology 1975 Jan;24(1):1-8.
18. Walsh S, Finn DP, Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience 2011 Feb;175:251-61.
19. Arnold JC, Salvatore MF. Getting to compliance in forced exercise in rodents: a critical standard to evaluate exercise impact in aging-related disorders and disease. Journal of Visualized Experiments 2014 Aug;(90):51827.
20. Stavrovskaya AV, Voronkov DN, Yamshchikova NG, Olshanskiy AS, Khudoerkov RM, Khaspekov LG, Illarioshkin SN. Morphochemical evaluation of neurotransplantation outcomes in experimental parkinsonism. Annals of Clinical and Experimental Neurology 2015;9(2):28-32 (In Russian).
21. Stavrovskaya AV, Novosadova EV, Olshanskiy SA, Yamshchikova NG, Gushchina AS, Arsenyeva EL, Grivennikov IA, Illarioshkin SN. Effect of cell genome editing on the outcome of neurotransplantation in experimental parkinsonism. Modern Technologies in Medicine 2017;9(4):7-14 (In Russian).
22. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957 Nov;180(4596):1200.
23. Coplaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987 Sep;26(9):1431-40.
24. Gossel M, Schmidt WJ, Löscher W, Zajaczkowski W, Danysz W. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. Journal of Neural Transmission. Parkinson’s Disease and Dementia Section 1995;10(1):27-39.
25. Shugalev NP, Stavrovskaya AV, Yamshchikova NG, Olshanskiy AS, Miroshnichenko EV. Reproduction of passive avoidance reactions after neurotensin microinjection into nucleus accumbens of rat brain against the background of reserpine action. IP Pavlov Journal of Higher Nervous Activity 2012 May-Jun;62(3):357-63 (In Russian).
26. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience 2000 Dec;3(12):1301-6.
27. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson’s disease. Journal of Neural Transmission. Supplementum 2006;(70):147-51.
28. Schmidt W, Alam MJ. Controversies on new animal models of Parkinson’s disease pro and con: the rotenone model of Parkinson’s disease (PD). Journal of Neural Transmission. Supplementum 2006;(70):273-6.
29. Alam M, Schmidt WJ. L-DOPA reverses the hypokinetic behavior and rigidity in rotenone-treated rats. Behavioural Brain Research 2004 Aug;153(2):439-46.
30. Watabe M, Nakaki T. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Molecular Pharmacology 2008 Oct;74(4):933-40.
31. Höglinger GU, Oertel WH, Hirsch EC. The rotenone model of parkinsonism – the five years inspection. Journal of Neural Transmission. Supplementum 2006;(70):269-72.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]